Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

3.250 +0.030 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
Company to disclose new programs from existing unnamed pre-clinical pipeline 
From Relay Therapeutics, Inc.
Via GlobeNewswire
5 Of 7 AI Categories Rose, Slightly,Over Past Week
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week. 
Via Talk Markets
Topics Artificial Intelligence
Key Takeaways From Relay Therapeutics Analyst Ratings
 
Via Benzinga
Relay Therapeutics: Q4 Earnings Insights
 
Via Benzinga
Relay Therapeutics's Earnings: A Preview
 
Via Benzinga
The 7 AI Categories Declined, On Average, The First Week Of May
Via Talk Markets
Topics Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
AI Surge Ending: Only One Category Was Up This Week
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over. 
Via Talk Markets
Topics Artificial Intelligence
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities. 
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
The 7 Best Penny Stocks for 200% Returns
Penny stocks often possess significant upside and these are no different with 200% returns expected by analysts. 
Via InvestorPlace
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces $30 Million Private Placement Financing
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Index Up 26% In December
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Relay Therapeutics: Here's What You Need To Know
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.